Aptamers for targeting coagulation factor XIII and uses thereof

1. An aptamer specific to coagulation factor XIII (FXIII) comprising a polynucleotide sequence at least 90% identical to SEQ ID NO: 1, wherein the aptamer has the polynucleotide sequence of SEQ ID NO: 2, or SEQ ID NO: 3, or SEQ ID NO: 4.

2. The aptamer of claim 1 , wherein the aptamer further comprising a reporter, a contrast agent, a nanoparticle, or an anti-thrombotic agent conjugated thereto.

3. The aptamer of claim 2 , wherein the reporter is acridine orange, acridine yellow, alkaline phosphatase (AP), auramine, benzoxadiazole, bilirubin, biotin, blue fluorescent protein (BFP), 6′-carboxyfluorescein (FAM), cascade blue, cresyl violet, crystal violet, cyan fluorescent protein (CFP), cyanine, eosin, fluorescein, fluorescein isothiocyanate, glutathione-S-transferase (GST), green fluorescence protein (GFP), horseradish peroxidase (HRP), indocarbocyanine, malachite green, merocyanine, Nile blue, Nile red, nitrobenzoxadiazole, orotidine 5′-phosphate decarboxylase, oxacarbocyanine, peridinin chlorophyll, phycoerythrin, phthalocyanine, porphine, proflavine, pyridyloxazole, red fluorescent protein (RFP), rhodamine, thiacarbocyanine, thioredoxin (TRX), or yellow fluorescent protein (YFP).

4. The aptamer of claim 2 , wherein the contrast agent is a barium-sulfate-, gadolinium-, or iodine-based contrast agent.

5. The aptamer of claim 2 , wherein the nanoparticle is aluminium oxide particle, boron particle, calcium particle, carbon nanotube, cerium oxide particle, clay particle, copper particle, diamond particle, gold particle, graphene particle, hydroxy acid particle, hydroxyapatite particle, iron particle, kojic acid particle, liposome, manganese particle, molybdenum particle, palladium particle, platinum particle, phosphorus particle, potassium particle, silicon dioxide particle, silver particle, sodium silicate particle, titanium dioxide particle, ytterbium tri fluori de particle, zinc particle, zinc oxide particle, or zirconium dioxide particle.

6. The aptamer of claim 2 , wherein the anti-thrombotic agent is an anticoagulantor, an antiplatelet agent, or a thrombolytic agent.

7. The aptamer of claim 6 , wherein the anticoagulantor is selected from the group consisting of, Acenocoumarol, Antithrombin III, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Certoparin, Clorindione, Coumatetralyl, Dabigatran, Dalteparin, Danaparoid, Darexaban, Dermatan sulfate, Defibrotide, Desirudin, Dicoumarol, Diphenadione, Drotrecogin, Edoxaban, Efegatran, Enoxaparin, Ethyl biscoumacetate, Fondaparinux, Heparin, Heparinoid, Hirudin, Idraparinux, Inogatran, Lepirudin, Melagatran, Nadroparin, Otamixaban, Parnaparin, Phenindione, Phenprocoumon, Ramatroban, Reviparin, Rivaroxaban, Sulodexide, Tinzaparin, Tioclomarol, Warfarin, and Ximelagatran.

8. The aptamer of claim 6 , wherein the antiplatelet agent is selected from the group consisting of, Abciximab, Acetylsalicylic acid, Aloxiprin, Aspirin, Beraprost, Cangrelor, Carbasalate calcium, Cilostazol, Clopidogrel, Cloricromen, Dipyridamole, Ditazole, Elinogrel, Eptifibatide, Iloprost, Indobufen, Orbofiban, Picotamide, Prasugrel, Prostacyclin, Roxifiban, Sibrafiban, Terbogrel, Terutroban, Thienopyridine, Ticagrelor, Ticlopidine, Tirofiban, Treprostinil, Triflusal, and Vorapaxar.

9. The aptamer of claim 6 , wherein the thrombolytic agent is selected from the group consisting of, Alteplase, Ancrod, Anistreplase, Brinase, Desmoteplase, Fibrinolysin, Monteplase, Reteplase, Saruplase, Streptokinase, Tenecteplase, and Urokinase.

10. A method for treating a disease associated with thrombosis in a subject, comprising administering to the subject an effective amount of the aptamer of claim 6 .

11. The method of claim 10 , wherein the anticoagulantor is selected from the group consisting of, Acenocoumarol, Antithrombin III, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Certoparin, Clorindione, Coumatetralyl, Dabigatran, Dalteparin, Danaparoid, Darexaban, Dermatan sulfate, Defibrotide, Desirudin, Dicoumarol, Diphenadione, Drotrecogin, Edoxaban, Efegatran, Enoxaparin, Ethyl biscoumacetate, Fondaparinux, Heparin, Heparinoid, Hirudin, Idraparinux, Inogatran, Lepirudin, Melagatran, Nadroparin, Otamixaban, Parnaparin, Phenindione, Phenprocoumon, Ramatroban, Reviparin, Rivaroxaban, Sulodexide, Tinzaparin, Tioclomarol, Warfarin, and Ximelagatran.

12. The method of claim 10 , wherein the antiplatelet agent is selected from the group consisting of, Abciximab, Acetylsalicylic acid, Aloxiprin, Aspirin, Beraprost, Cangrelor, Carbasalate calcium, Cilostazol, Clopidogrel, Cloricromen, Dipyridamole, Ditazole, Elinogrel, Eptifibatide, Iloprost, Indobufen, Orbofiban, Picotamide, Prasugrel, Prostacyclin, Roxifiban, Sibrafiban, Terbogrel, Terutroban, Thienopyridine, Ticagrelor, Ticlopidine, Tirofiban, Treprostinil, Triflusal, and Vorapaxar.

13. The method of claim 10 , wherein the thrombolytic agent is selected from the group consisting of, Alteplase, Ancrod, Anistreplase, Brinase, Desmoteplase, Fibrinolysin, Monteplase, Reteplase, Saruplase, Streptokinase, Tenecteplase, and Urokinase.

14. The method of claim 10 , wherein the subject is a human.

15. The method of claim 10 , wherein the disease associated with thrombosis is venous thrombosis or arterial thrombosis.

16. The method of claim 15 , wherein the venous thrombosis is branch retinal vein occlusion, BuddChiari syndrome, cavernous sinus thrombosis, central retinal vein occlusion, cerebral venous sinus thrombosis, deep vein thrombosis, jugular vein thrombosis, mesenteric vein thrombosis, PagetSchroetter disease, parodoxical embolism, portal vein thrombosis, pulmonary embolism, renal vein thrombosis, or splenic vein thrombosis.

17. The method of claim 15 , wherein the arterial thrombosis is hepatic artery thrombosis, limb ischemia, myocardial infarction, or stroke.